(NRIFF) Mcap 36 M/Cash 18 M/ 2x Approvals +Profitability THI

[Biotechmaster]

Nuvo is definitely one of the most undervalued stock in the Biotech Sector . Nuvo is a unknown Gem thats the only problem with this Goldmine but this will change soon with a Nasdaq or Amex listing which is planned for mid year .

Nuvo has already 2 Products (Pennsaid +Synera) on the Market .The next Product (Pliaglis) awaiting US and EU approval which will happen by mid 2012 .Nuvo will get $ 8 M milestone payment upon EU launch from their Partner Galderma who holds the worldwide rights for Pliaglis .(MORE INFOS IN THEIR PRESENTATION LINK BELOW)

Nuvo will be profitable by late 2012 or early 2013 the future looks definitely very good for this Goldmine .

Market cap of $ 36 M is really a PURE GIFT for a Biotech Company which has almost 3 Products on the Market and $ 18 M in Cash .

Fantastic entry point at this HUGE bargain level .Patience will payoff big time here .GLTA

MY TARGET: $0.50++ WITHIN 12 MONTHS


Nuvo Research (NRI.TO) or (NRIFF.PK) Canadian Stock

Market Cap : $ 39.4 M
Cash: $ 18.1 M
Price 0.07 $

NO DEBT



Presentation Jan 2012..A MUST READ !!!

20IR%20Presentation%20January_2012.pdf



Insider Activity




UPCOMING MILESTONES 2012 :

Growing Pennsaid U.S. sales = higher royalty revenue
Covidien sNDA for Pennsaid 2%

Pliaglis approval and launch in the U.S. and E.U. = new royalty
revenue and milestone payments ( 15% royalties + $8 M milestone upon EU launch )

Relaunch Synera in the U.S. and expand in the E.U.

Announce action plan for WF10 development


Corporate Profile
Nuvo Research Inc. is a publicly traded (TSX:NRI), Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development and by in-licensing and acquisition.

The Company's Pain Group, located in West Chester, Pennsylvania, is focused on the development and commercialization of topically delivered pain products. The Company's product portfolio includes Pennsaid